Navigation Links
Cancer drugs in development nearly doubled since 1995

The number of drugs being developed for the treatment of cancer has nearly doubled during the past six years, according to a new survey of pharmaceutical companies. Currently, 170 pharmaceutical and biotechnology firms various Cancer Institutes are investigating 402 compounds for the treatment of various cancers, up from 215 in 1995. Many of the drugs are alternatives to standard radiation and chemotherapy. For lung cancer, the leading cause of cancer-related death in the United States, there are 68 drugs in the pipelines of various companies. Experimental drugs for the treatment of breast cancer total 59, while there are 55 for colon cancer, 52 for skin cancer and 52 for prostate cancer. Other cancers being targeted include solid tumors, sarcomas, pancreatic cancer, ovarian cancer, multiple myeloma, lymphoma, liver cancer, leukemia, kidney cancer, brain cancer, stomach cancer and bladder cancer. Of the drugs in development, 17 are waiting for Food and Drug Administration approval (FDA). Thanks in large part to medicines developed in the past decade, cancer deaths are on the decline. But cancer is still the second leading cause of American deaths by disease.
'"/>




Page: 1

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
10. Cancer patients turning to Internet for information
11. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Leading ... that address medical conditions resulting from a breakdown ... has appointed Greg Doyle as chief ... Leading BioSciences, executive management team and board of ... chief financial officer. He will provide continued leadership ...
(Date:6/23/2016)... June 23, 2016 Research and ... in Europe 2016 Edition: The New Global Agenda " ... OTC Distribution in Europe - ... explores and tracks change. It identifies the driving factors coming ... the consumer healthcare industry now and in the future. It ...
(Date:6/23/2016)... June 23, 2016 The ... the development of combination therapies trend is expected ... treatment of CLL were available only in the ... are chlorambucil in combination with prednisone, and a ... a growing trend of developing combination therapies to ...
Breaking Medicine Technology: